|
Shaanxi Jiuyuan Biotechnology Co.,Ltd
|
Resveratrol interferes with all three stages of carcinogenesis initiation, promotion and progression. Experiments in cell cultures of varied types and isolated subcellular systems in vitro imply many mechanisms in the pharmacological activity of resveratrol. In some lineages of cancer cell culture, resveratrol has been shown to induce apoptosis, which means it kills cells and may kill cancer cells.Resveratrol has been shown to induce Fas/Fas ligand mediated. Resveratrol also possesses antioxidant and anti-angiogenic properties. |
Send Inquiry
|
|
SICHUAN UNIWELL BIOTECHNOLOGY CO.,LTD
|
Product Name: Polygonum Cuspidatum Extract
CAS NO.: 501-36-0
Molecular formula: C14H12O3
Molecular weight: 228.243
Extraction solvent:Ethyl acetate, Ethanol and water
Country of Origin: China
Irradiation: Non-irradiated
Identification: TLC
GMO: Non-GMO
Carrier/Excipients: None
It was extracted from the dry root of polygonum cuspidatum sieb.et.zucc, with brown yellow to off white powder, special smell and light taste. Active ingredients is resveratrol, it is a kind of non flavonoid polyphenol organic compound, which is an antitoxin produced by many plants when stimulated. Natural resveratrol has CIS and trans structures. In nature, it mainly exists in trans conformation. The two structures can combine with glucose to form CIS and trans resveratrol glycosides. CIS and trans resveratrol glycosides can release resveratrol under the action of glucosidase in intestine. Trans resveratrol can be converted to CIS isomer under UV irradiation.
Function:
*Reduce blood lipids and the incidence of coronary disease;provide cardiovascular system with a special protection;
* Regulate ratio of low density lipoprotein(LDL)
* Reduce platelet aggregation,etc;
* Anti-oxidation,anti-aging,prevent and treatment of cardiovascular diseases,prevent and treatment of cancer,Alzheimer's disease prevention and increasing the strength;
* Has apparent effects on diabetes prevention and control; |
Send Inquiry
|
Pharma Sources Insight January 2025
